We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SARS-CoV-2 Virus in Cancer Patients: A New Unknown in an Unsolved Equation.
- Authors
Martín, Margarita; Vallejo, Carmen; López-Campos, Fernando; Quereda, Carmen; Muñoz, Teresa; Sánchez-Conde, Matilde; Dominguez, Jose Antonio; Soriano, Cruz; Martín, Mercedes; Suárez-Carantoña, Cecilia; Muriel, Alfonso; Garrido, Pilar; Acero, Julio; Alvarez-Diaz, Ana; de la Pinta, Carolina; Martínez-García, Laura; Hernánz, Raúl; Fernández, Eva; Alarza, Marina; Hervás, Asunción
- Abstract
Introduction: Cancer patients are more susceptible to infections, and infection can be more severe than in patients without cancer diagnosis. We conducted this retrospective study in patients admitted for SARS-CoV-2 infection in order to find differences in inflammatory markers and mortality in cancer patients compared to others. Methods: We reviewed the electronic records of patients admitted for SARS-CoV-2 infection confirmed by PCR from March to September 2020. Data on socio-demographics, comorbidities, inflammatory makers, and cancer-related features were analyzed. Results: 2,772 patients were admitted for SARS-CoV-2, to the Hospital Universitario Ramón y Cajal in Madrid during this period. Of these, 2,527 (91%) had no history of neoplastic disease, 164 (5.9%) patients had a prior history of cancer but were not undergoing oncological treatment at the time of infection, and 81 (2.9%) were in active treatment. Mortality in patients without a history of cancer was 19.5%, 28.6% for patients with a prior history of cancer, and 34% in patients with active cancer treatment. Patients in active oncology treatment with the highest mortality rate were those diagnosed with lung cancer (OR 5.6 95% CI: 2.2–14.1). In the multivariate study, active oncological treatment (OR 2.259 95% CI: 1.35–3.77) and chemotherapy treatment (OR 3.624 95% CI: 1.17–11.17), were statistically significant factors for the risk of death for the whole group and for the group with active oncological treatment, respectively. Conclusion: Cancer patients on active systemic treatment have an increased risk of mortality after SARS-CoV-2 infection, especially with lung cancer or chemotherapy treatment.
- Subjects
COVID-19; CONFIDENCE intervals; INFLAMMATION; MULTIVARIATE analysis; RETROSPECTIVE studies; LUNG tumors; CANCER patients; COMPARATIVE studies; TUMORS; SOCIODEMOGRAPHIC factors; ODDS ratio; POLYMERASE chain reaction; COMORBIDITY
- Publication
Oncology, 2023, Vol 101, Issue 1, p1
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000525802